- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Creos International suspends shares
X-ray generator developer Creos International of Fife, Scotland, has been encountering financial problems of late. The company last month requested that its shares be suspended from trading on the Alternative Investment Market of the U.K. while it
X-ray generator developer Creos International of Fife, Scotland, has been encountering financial problems of late. The company last month requested that its shares be suspended from trading on the Alternative Investment Market of the U.K. while it considers its financial position. The company has closed its subsidiary, Creos Limited, and is seeking the appointment of a provisional liquidator.
The companys compact x-ray generator technology will live on, however. In December, Creos Limiteds U.S. subsidiary, Creos Inc., sold its business and assets to Colorado businessman Peter Cooper, who founded a new, private company, Creos Technologies of Englewood, CO. Creos Technologies employs 33 people and manufactures the high-powered, high-frequency x-ray generators initially developed by Creos International (SCAN 7/13/94). Creos International holds a residual interest in the new company.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
